EW
Edwards Lifesciences
$85.88
▼ 1.7%Updated Today 7:15 PM ET
▲ Up 18.1% over the last 12 months
Market Cap
$50.30B
P/E
45.84x
Forward P/E (est.)
65.49x
ROE
10.6%
Revenue Growth
13.8%
EPS Growth
-73.2%
Profit Margin
17.4%
FCF Yield
2.9%
Debt / Equity
0.06x
ROIC
9.0%
Interest Coverage
71.83x
Current Ratio
4.42x
Dividend Yield
—
Implied Growth (rev. DCF)
6.2%
Rating Score
47/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what EW's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. EW trades near $85.88, above its 50-day average ($83.15) and 200-day average ($81.93). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 52 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. EW's is $2.58 (~3.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month EW found buyers near $81.23 (support) and sellers near $89.60 (resistance); its 52-week range is $72.30–$89.60. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Edwards Lifesciences (EW) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $50.30B.
In its latest reported year it generated about $6.07B in revenue and $1.07B in net profit.
Our model rates EW Neutral (47/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
3.8%
Revenue moved from $5.23B in 2021 to $6.07B in 2025, a 3.8% compound annual growth rate. The most recent year grew a steady 13.8% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
78.0%
Operating Margin
20.8%
Net Margin
17.7%
ROE
10.6%
Edwards Lifesciences keeps about 17.4% of each sales dollar as net profit, with a 78.0% gross margin and 20.8% operating margin. Return on equity is 10.6% and return on invested capital about 9.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$600.00M
Net Debt
-$1.85B
Net cash position
Net Debt / EBITDA
-1.46x
Debt / Equity
0.06x
Leverage: debt-to-equity is 0.1x, and operating profit covers interest about 71.8x, with a current ratio of 4.4x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $600.00M of total debt against $2.45B of cash.
Operating CF
$1.60B
Free Cash Flow
$1.33B
FCF Margin
22.0%
In the latest year Edwards Lifesciences produced about $1.60B of operating cash flow and $1.33B of free cash flow after capital spending. That is a free-cash-flow yield of about 2.9% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
45.84x
P/S
8.4x
P/B
4.72x
EV / EBITDA
34.6x
EW trades at 45.8x trailing earnings (about 65.5x on estimated forward earnings), 8.4x sales, and 4.7x book value. Reverse-engineering today's price implies the market expects roughly 6.2% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How EW stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), EW ranks #42 of 59 by our overall rating. It trades at a premium versus the sector on earnings (45.8x P/E vs. 25.4x median) with a lower return on equity (10.6% vs. 14.9%) and faster revenue growth (13.8% vs. 7.9%).
P/E vs sector
45.8x
median 25.4x
ROE vs sector
10.6%
median 14.9%
Growth vs sector
13.8%
median 7.9%
Sector rank
#42
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$102.26 – $168.00
vs. $85.88 today · expected CAGR 4% – 14%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $6.92B | $7.89B | $8.99B | $10.25B | $11.68B |
| Net income | $1.25B | $1.42B | $1.62B | $1.84B | $2.10B |
| EPS | $2.16 | $2.47 | $2.81 | $3.20 | $3.65 |
| Share price (low) | $60.55 | $69.02 | $78.68 | $89.70 | $102.26 |
| Share price (high) | $99.47 | $113.39 | $129.27 | $147.37 | $168.00 |
| CAGR (low–high) | -30% / 16% | -10% / 15% | -3% / 15% | 1% / 14% | 4% / 14% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for EW:
- Revenue is growing 13.8% a year, a sign of real demand.
- High net margins (17.4%) point to pricing power or efficiency.
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
The case against EW:
- A rich 45.8x earnings multiple prices in a lot of growth.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 45.8x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Edwards Lifesciences is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 45.8x earnings, which our model scores Neutral (47/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.